Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal Function

• Status: Completed
• Trial end date: 2009-09-01

Summary

To characterize the pharmacokinetics of G3139 in subjects with normal, mildly impaired, and moderately impaired renal function who receive Genasense 3 mg/kg/day by continuous intravenous infusion for 2 days (48 hours).

• Phase: Phase 1

Details

• Lead Sponsor: Genta Incorporated
• Treatments: Oblimersen